Seelos Therapeutics, Inc., a biopharmaceutical company, has filed a Form S-8 registration statement with the Securities and Exchange Commission (SEC) on March 6, 2024. The filing is to register an additional 106,206 shares of its common stock under the company's Amended and Restated 2012 Stock Long Term Incentive Plan. This plan, which includes shares issuable pursuant to options granted, has already received approval from Seelos Therapeutics' stockholders. The newly registered shares add to the previously registered 680,429 shares under the same plan, as detailed in prior registration statements. The company's Annual Report for the fiscal year ended December 31, 2023, and Current Reports filed on January 10 and January 22, 2024, are incorporated by reference into this registration statement. Seelos Therapeutics, based in New York, is incorporated in Nevada and has provided contact information for investors to request copies of the referenced filings without charge.

Seelos Therapeutics, Inc., a biopharmaceutical company, has filed a Form S-8 registration statement with the Securities and Exchange Commission (SEC) on March 6, 2024. The filing is to register an additional 106,206 shares of its common stock under the company's Amended and Restated 2012 Stock Long Term Incentive Plan. This plan, which includes shares issuable pursuant to options granted, has already received approval from Seelos Therapeutics' stockholders. The newly registered shares add to the previously registered 680,429 shares under the same plan, as detailed in prior registration statements. The company's Annual Report for the fiscal year ended December 31, 2023, and Current Reports filed on January 10 and January 22, 2024, are incorporated by reference into this registration statement. Seelos Therapeutics, based in New York, is incorporated in Nevada and has provided contact information for investors to request copies of the referenced filings without charge.